Lymphoma Hub

Lymphoma Hub

The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.

Tämä podcast on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi podcastin jaksot saattavat sisältää mainontaa.

Jaksot(53)

SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL

SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub was pleased to speak to Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We asked about the latest updates from ...

12 Elo 20244min

SYMPHONY 1: A trial update

SYMPHONY 1: A trial update

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked for an updat...

9 Tammi 20235min

Novel therapies in chronic lymphocytic leukemia: An update.

Novel therapies in chronic lymphocytic leukemia: An update.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Chan Cheah, University of Western Australia, Perth, AU. We asked for an update on novel th...

5 Tammi 20238min

What are the CAR T-cell therapies on the horizon for lymphoma?

What are the CAR T-cell therapies on the horizon for lymphoma?

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Pere Barba, Hospital Universitari Vall d'Hebron, Barcelona, ES. We asked, What are the chi...

3 Tammi 20234min

How do you choose among different BTK inhibitors for treating CLL?

How do you choose among different BTK inhibitors for treating CLL?

The Lymphoma Hub was pleased to speak with Francesc Bosch, Vall d’Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, How do you choose among different BTK inhibitors for treating CLL?Bosch ope...

2 Joulu 20227min

What are the latest advances in basal PET/CT for Hodgkin and non-Hodgkin lymphoma?

What are the latest advances in basal PET/CT for Hodgkin and non-Hodgkin lymphoma?

The Lymphoma Hub was pleased to speak with Astrid Pavlovsky, FUNDALEU, Buenos Aires, AR. We asked, What are the latest advances in basal PET/CT for Hodgkin and non-Hodgkin lymphoma?Pavlovsky outlines ...

7 Marras 20229min

ASCT in DLBCL – is it over?

ASCT in DLBCL – is it over?

As part of our biannual steering committee meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, USA, chaired a discussion session on the current and future role of autologous stem...

3 Elo 202217min

What is on the horizon for the frontline treatment of MCL?

What is on the horizon for the frontline treatment of MCL?

During the ASCO2022 congress, the Lymphoma Hub was pleased to speak with Anita Kumar, Memorial Sloane Kettering Cancer Center, New York, US. We asked, What is on the horizon for the frontline treatmen...

25 Heinä 20227min

Suosittua kategoriassa Koulutus

rss-murhan-anatomia
psykopodiaa-podcast
aamukahvilla
adhd-podi
voi-hyvin-meditaatiot-2
rss-rahamania
rss-niinku-asia-on
rss-liian-kuuma-peruna
rss-vapaudu-voimaasi
rss-keskeneraiset-aidit
rss-koira-haudattuna
koulu-podcast-2
ihminen-tavattavissa-tommy-hellsten-instituutti
kesken
rss-arkea-ja-aurinkoa-podcast-espanjasta
rss-uskonto-on-tylsaa
rahapuhetta
rss-duodecim-lehti
rss-luonnollinen-synnytys-podcast
jari-sarasvuo-podcast